Loxo Oncology Inc (LOXO) Insider Sells $296,919.88 in Stock

Loxo Oncology Inc (NASDAQ:LOXO) insider Naarden Jacob Van sold 3,082 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $96.34, for a total transaction of $296,919.88. Following the completion of the sale, the insider now directly owns 1,541 shares in the company, valued at approximately $148,459.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Naarden Jacob Van also recently made the following trade(s):

  • On Wednesday, January 17th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $88.21, for a total transaction of $271,863.22.
  • On Friday, December 15th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $81.19, for a total transaction of $250,227.58.
  • On Tuesday, November 28th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $74.50, for a total transaction of $229,609.00.

Shares of Loxo Oncology Inc (LOXO) traded up $3.43 on Wednesday, hitting $104.35. 504,068 shares of the company traded hands, compared to its average volume of 344,973. The stock has a market capitalization of $2,812.33, a P/E ratio of -17.31 and a beta of 2.57. Loxo Oncology Inc has a fifty-two week low of $40.01 and a fifty-two week high of $108.50.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Great West Life Assurance Co. Can lifted its stake in shares of Loxo Oncology by 195.8% during the third quarter. Great West Life Assurance Co. Can now owns 2,958 shares of the biopharmaceutical company’s stock valued at $275,000 after buying an additional 1,958 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Loxo Oncology by 38.8% during the second quarter. The Manufacturers Life Insurance Company now owns 15,597 shares of the biopharmaceutical company’s stock valued at $1,251,000 after buying an additional 4,357 shares during the period. Parametrica Management Ltd purchased a new position in shares of Loxo Oncology during the third quarter valued at approximately $500,000. Cornerstone Capital Management Holdings LLC. purchased a new position in shares of Loxo Oncology during the third quarter valued at approximately $847,000. Finally, Vanguard Group Inc. lifted its stake in shares of Loxo Oncology by 24.7% during the second quarter. Vanguard Group Inc. now owns 914,719 shares of the biopharmaceutical company’s stock valued at $73,351,000 after buying an additional 181,471 shares during the period.

Several brokerages have issued reports on LOXO. Zacks Investment Research raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. William Blair started coverage on shares of Loxo Oncology in a research note on Tuesday, November 28th. They set an “outperform” rating on the stock. Citigroup reduced their price objective on shares of Loxo Oncology from $112.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, November 16th. BidaskClub raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Finally, JMP Securities raised shares of Loxo Oncology from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $77.18 to $95.00 in a research note on Tuesday, November 14th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Loxo Oncology has an average rating of “Buy” and a consensus target price of $97.33.

COPYRIGHT VIOLATION WARNING: “Loxo Oncology Inc (LOXO) Insider Sells $296,919.88 in Stock” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/02/14/loxo-oncology-inc-loxo-insider-sells-296919-88-in-stock.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply